
WHAT IS CLAIMED IS:

1. A compound of Formula I:



, or a pharmaceutically acceptable salt or solvate thereof, wherein:

------ indicates a single bond or a double bond such that all valences are satisfied;

X^1, X^2, X^3, and X^4 are selected from N and CR^a, with the proviso that not more than two of X^1, X^2, X^3, and X^4 are N;

one of Y^1 and Y^2 is N and the other of Y^1 and Y^2 is C;

each R^a is independently selected from H, halo, C_1-C_4alkyl, and C_1-C_4alkoxy;


R^1 is heteroaryl optionally substituted with one, two, three, four, five, or six substituents selected from halo, hydroxy, oxo, C_1-C_4alkyl, aminoC_1-C_4alkyl, hydroxyC_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4alkoxyC_1-C_4alkyl, 3-8 membered heterocyclyl, and 3-8 membered heterocyclylC_1-C_4alkyl, with the proviso that the number of substituents does not exceed the number of substitutable positions;

R^2 is selected from cycloalkyl, cycloalkenyl, heterocyclyl, and aminoheterocyclyl, all of which can be optionally substituted with one, two, three, four, or five substituents selected from D, halo, hydroxy, oxo, and C_1-C_4alkyl;

R^2 is substituted with one R^3;

R^3 is selected from aryl, heteroaryl, $-C(O)R^{31}$, $-C(O)OR^{31}$, $-C(O)NR^{31}R^{32}$, $-S(O)_2NR^{31}R^{32}$, $-S(O)(NR^{33})R^{31}$, $-S(O)(NR^{33})NR^{31}R^{32}$, $-C(S)NR^{31}R^{32}$, C_3-C_8cycloalkyl, 3-8 membered heterocyclyl, and C_1-C_4alkyl, all of which can be optionally substituted with one, two, three, four, or five R^{30};

each R^{30} is independently selected from D, halo, aryl, $-OR^{300}$, $-NR^{300}R^{303}$, $-S(O)_rR^{300}$, $-C(O)R^{300}$, $-C(=CR^{34}R^{35})R^{300}$, and



;

r is selected from 0, 1, and 2;

each R^{300} is independently selected from C_1-C_6alkyl, C_3-C_7cycloalkyl, aryl, heteroaryl, 3-8 membered heterocyclyl, and 3-8 membered heterocyclylaryl, all of which can be optionally substituted with one, two, three, four, or five substituents selected from D, halo, hydroxy, amino, alkylamino, cyano, C_1-C_4alkyl, C_1-C_4haloalkyl, and C_1-C_4alkoxy;

each R^{301} is independently selected from H, halo, and C_1-C_4alkyl;

each R^{302} is independently selected from H, F, hydroxyl, amino, alkylamino, oxo, and C_1-C_4alkyoxy;

each R^{303} is independently selected from H and C_1-C_4alkyl;

n, o, and p are each independently selected from 0, 1, 2, 3, and 4;

each R^{31} is independently selected from C_1-C_8alkyl, arylC_1-C_4alkyl, heteroarylC_1-C_4alkyl, heterocyclyl, heterocyclylC_1-C_4alkyl, cycloalkyl, and cycloalkylC_1-C_4alkyl, all of which can be optionally substituted with one, two, three, four, or five substituents selected from D, halo, cyano, hydroxy, amino, $-OCF_3$, C_1-C_4alkyl, C_1-C_4haloalkyl, C_1-C_4alkoxy, hydroxyC_1-C_4alkyl, $-S(O)_2NR^{304}R^{305}$, $-C(O)OR^{304}R^{305}$, $-C(O)NR^{304}R^{305}$, and $-NR^{304}C(O)R^{305}$;

each R^{304} and R^{305} is independently selected from H and C_1-C_4alkyl;

each R^{32} is independently selected from H and C_1-C_4alkyl; or

R^{31} and R^{32} together with the atom to which they are connected to form a 5-8 membered heterocyclyl, optionally substituted with one, two, or three substituents selected from D, halo, cyano, C_1-C_4alkyl, C_1-C_4haloalkyl, and $-C(O)NR^{34}R^{35}$; and

each R^{34} and R^{35} is independently selected from H, C_1-C_4alkyl, and C_1-C_4haloalkyl; and

each R^{33} is independently selected from H, C_1-C_4alkyl, C_1-C_4haloalkyl, and –$C(O)R^{34}$; or


R^{31} and R^{33} together with the atoms to which they are connected form a 4-8 membered heterocyclyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X^1 is N, X^2 is CR^a, X^3 is CR^a, and X^4 is CR^a.

3. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein Y^1 is N, Y^2 is C, X^1 is CR^a, X^2 is N, X^3 is CR^a, and X^4 is CR^a.

4. The compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein Y^1 is N, Y^2 is C, X^1 is CR^a, X^2 is CR^a, X^3 is CR^a, and X^4 is CR^a.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt or solvate thereof, wherein R^1 is







and

R^{10} is CH_3.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is optionally substituted heterocyclyl.

7. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt or solvate thereof, wherein R^2 is selected from:




; and

;

indicates a single bond or a double bond such that all valences are satisfied.

8. The compound of any one of claims 1 to 7, or a pharmaceutically acceptable salt or solvate thereof, having Formula Ia:





wherein a and b are each independently selected from 1, 2, and 3; and

Q is selected from -CH- and -N-, with the proviso that if Q is -N-, a and b are not 1.

9. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is heteroaryl optionally substituted with one R^{30}.

10. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is selected from:






; and


wherein A^1 is selected from O, S, and N.

11. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{30} is:



,

R^{300} is:




or ;

R^{301} is selected from H and C_1-C_4alkyl; and


R^{302} is selected from H and hydroxyl.

12. The compound of any one of claims 1 to 8, or a pharmaceutically acceptable salt or solvate thereof, wherein R^3 is selected from:




, , , and .

13. The compound of claim 12, or a pharmaceutically acceptable salt or solvate thereof, wherein R^{31} is selected from:





, , , ,





wherein R^{31a} is selected from H, D, alkylamino, C_1-C_4alkyl, and -CF_3, and R^{31b} is selected from H, D, halo, hydroxy, amino, alkylamino, C1-C4alkyl, -CF_3, and -OCF_3.

14. The compound of claim 13, wherein R^{31} is



,








,


















,


or .

15. The compound of claim 14, wherein R^{31a} is H or -CH_3 and R^{31b} is H, halo, -CH_3, -OCF_3, or -CF_3.

16. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from the group consisting of:














,

,

,

,

,

,





,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,

,

,


,

,

,

,

,

,

,

,

,

,

,

,













,

,

,















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




















,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,





















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,























,



















,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



















,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,






















,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,







,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,



















,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,
















,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,





,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

, and

.

17. A pharmaceutical composition comprising the compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

18. A kit comprising the compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of claim 17, and instructions for use.

19. Use of the compound of any one of claims 1 to 16 or the pharmaceutical composition of claim 17 in the manufacture of a medicament for treating a demyelinating disease in a subject in need thereof.

20. The use of claim 19, wherein the demyelinating disease comprises an acute disseminated encephalomyelitis (ADEM), acute hemorrhagic leukoencephalitis, acute transverse myelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Alexander disease, Alzheimer's disease, aminoacidurias, amyotrophic lateral sclerosis, anti-MAG peripheral neuropathy, anti-MOG associated spectrum, Balo concentric sclerosis, brain injury, CAMFAK syndrome, Canavan disease, carbon monoxide toxicity, central pontine myelinolysis, cerebral hypoxia, cerebral ischemia, Charcot–Marie–Tooth disease, chronic inflammatory demyelinating polyneuropathy, chronic traumatic encephalopathy, clinically isolated syndrome (CIS), congenital cataract, copper deficiency associated condition, delayed post-hypoxic leukoencephalopathy, diffuse cerebral sclerosis of Schilder, diffuse myelinoclastic sclerosis, extrapontine myelinolysis Gaucher disease, Guillain–Barré syndrome, hereditary neuropathy, hereditary neuropathy with liability to

pressure palsy, HTLV-1–associated myelopathy, Hurler syndrome, hypomyelination, hypoxic brain injury, Krabbe disease, Leber hereditary optic atrophy and related mitochondrial disorders, leukodystrophic disorders, Marchiafava-Bignami disease, metachromatic leukodystrophy, multiple sclerosis, multiple system atrophy, myelinoclastic disorders, myelopathy, nerve injury, neuromyelitis optica (NMO), Niemann-Pick disease, optic neuropathy, optic neuritis, osmotic demyelination syndrome, Parkinson's disease, Pelizaeus-Merzbacher disease, peripheral neuropathy, phenylketonuria, progressive inflammatory neuropathy, progressive multifocal leukoencephalopathy, progressive subcortical ischemic demyelination, reperfusion injury, Schilder disease, solitary sclerosis, spinal cord injury, subacute sclerosing panencephalitis, Tabes dorsalis, Tay-Sachs disease, transverse myelitis, traumatic brain injury, tropical spastic paraparesis, vitamin B12 deficiency, cerebral palsy, or a combination thereof.

21. The use of claim 20, wherein the demyelinating disease is multiple sclerosis.

22. The use of claim 21, wherein the multiple sclerosis comprises a clinically isolated syndrome ("CIS"), relapsing-remitting MS ("RRMS"), secondary progressive MS ("SPMS"), primary progressive MS ("PPMS"), optic neuritis or transverse myelitis.

23. The use of any one of claims 19 to 22, wherein treating the demyelinating disease comprises reducing one or more symptoms associated with the demyelinating disease.

24. The use of claim 23, wherein the one or more symptoms comprise fatigue, dizziness, malaise, elevated fever and high body temperature, extreme sensitivity to cold in the hands and feet, weakness and stiffness in muscles and joints, weight changes, digestive or gastrointestinal problems, low blood pressure, high blood pressure, irritability, anxiety, depression, impaired vision, ataxia, clonus, spasms, dysarthria, weakness, clumsiness, hand paralysis, hemiparesis, genital anesthesia, sexual dysfunction, incoordination, paresthesias, ocular paralysis, impaired muscle coordination, loss of sensation, tingling, numbness, pain, neurological symptoms, impaired cognition, unsteady gait, balance problems, dizziness, spastic paraparesis, incontinence, hearing problems, speech problems, loss of olfaction, agusia, or combinations thereof.